NanoViricides, Inc. (OTCBB:NNVC) Heads Downward Before Weekend
NanoViricides, Inc. (OTCBB:NNVC) had a day in the red on Thursday, and we are yet to see on what note this biotech company faces the weekend. NVC is jut one among many tickers in this sector that are bidding for attention right now. In its first day of losses in four, NNVC lost tentative 3% to stand at 96 cents. On Wednesday, the ticker stopped at 99 cents, easily looking above the dollar threshold, but for now not managing to cross it. 
NNVCgot a boost from an interview with the Fox Network, where CEO Eugene Seymour, MD commented on the company’s technologies. Further, NNVC impresses with:
- $15.4 million cash
- $17.8 million total assets
- $7.7 million total liabilities
- $3.6 million quarterly net loss
- $36 million loss for 96 months
And now NNVC‘s press release and media appearance is packed together with another promotional mail. It’s strange that on the day of such active promotional and PR events NNVC would end with a drop, but the sentiment may be getting tired. This time, the pumper was BeaconEquity.com, taking up the ticker without compensation, along with several other mentions.
Of interest may be the mention of Montalvo Spirits, Inc. (OTCBB:TQLA), which has not seen promotion for a while, but had a rebounce in the past few days. TQLA is a relatively solid company that still has to prove itself with more robust revenues.
Early Friday’s trading also started with a decrease in price, recalling periods when NNVC was marking quite deep corrections within a day. Keep in mind this potential when deciding on your time horizon and the preferred size of your investment.
On the plus side, NNVC has signed an agreement with the British public health authorities, to test for viral diseases and propose anti-virals for salient infections such as dangerous infuenza strains that appear worldwide. Still, NNVC is quite far from actually releasing a drug, and the stock is quite vulnerable to news and sentiment.
Another bold innovator, Advanced Cell Technology, Inc. (OTCBB:ACTC) is showing a post-promotional slump, as stem cell promises tend to wear out and investors move away to the next exciting ticker with better publicity. NNVC has a highly contingent success, and while news on an upcoming drug may boost it, it is still best not to rely too much on growth and do your own research when you base your decisions.
